153 related articles for article (PubMed ID: 3199680)
1. Mineralocorticoid activity and the excretion of an oral potassium load in normal man.
Hené RJ; Koomans HA; Rabelink AJ; Boer P; Dorhout Mees EJ
Kidney Int; 1988 Nov; 34(5):697-703. PubMed ID: 3199680
[TBL] [Abstract][Full Text] [Related]
2. Natriuretic and kaliuretic response to potassium load: modulation by sodium intake.
van Buren M; Rabelink AJ; Bijlsma JA; Koomans HA
Nephrol Dial Transplant; 1993; 8(6):495-500. PubMed ID: 8394528
[TBL] [Abstract][Full Text] [Related]
3. Aldosterone in congestive heart failure: analysis of determinants and role in sodium retention.
Hensen J; Abraham WT; Dürr JA; Schrier RW
Am J Nephrol; 1991; 11(6):441-6. PubMed ID: 1840232
[TBL] [Abstract][Full Text] [Related]
4. Effect of mineralocorticoid activity on transtubular potassium gradient, urinary [K]/[Na] ratio, and fractional excretion of potassium.
Chacko M; Fordtran JS; Emmett M
Am J Kidney Dis; 1998 Jul; 32(1):47-51. PubMed ID: 9669423
[TBL] [Abstract][Full Text] [Related]
5. Effects of acute mineralocorticoid and glucocorticoid receptor blockade on the excretion of an acute potassium load in healthy humans.
van Buren M; Boer P; Koomans HA
J Clin Endocrinol Metab; 1993 Oct; 77(4):902-9. PubMed ID: 8408463
[TBL] [Abstract][Full Text] [Related]
6. Na(+) dependence of K(+) -induced natriuresis, kaliuresis and Na(+) /Cl(-) cotransporter dephosphorylation.
Jensen IS; Larsen CK; Leipziger J; Sørensen MV
Acta Physiol (Oxf); 2016 Sep; 218(1):49-61. PubMed ID: 27172453
[TBL] [Abstract][Full Text] [Related]
7. Dose-response relationships for spironolactone at steady state.
McInnes GT; Perkins RM; Shelton JR; Harrison IR
Clin Pharmacol Ther; 1982 Mar; 31(3):317-23. PubMed ID: 7060315
[TBL] [Abstract][Full Text] [Related]
8. Mineralo- and glucocorticoid effects on renal excretion of electrolytes.
Campen TJ; Vaughn DA; Fanestil DD
Pflugers Arch; 1983 Oct; 399(2):93-101. PubMed ID: 6647008
[TBL] [Abstract][Full Text] [Related]
9. Bioassay of aldosterone antagonists in normal human subjects: a relationship between the level of plasma uric acid before treatment and apparent drug responses.
Ramsay LE; Hessian P; Tidd MJ
Br J Clin Pharmacol; 1975 Jun; 2(3):271-6. PubMed ID: 1234508
[TBL] [Abstract][Full Text] [Related]
10. Steady-state relative potency of aldosterone antagonists: spironolactone and prorenoate.
McInnes GT; Shelton JR; Harrison IR
Clin Pharmacol Ther; 1981 May; 29(5):679-86. PubMed ID: 7214797
[TBL] [Abstract][Full Text] [Related]
11. The effect of mineralocorticoid administration on urine free dopamine in man.
Oates NS; Perkins CM; Lee MR
Clin Sci (Lond); 1980 Jan; 58(1):77-82. PubMed ID: 6986226
[TBL] [Abstract][Full Text] [Related]
12. Relative potency of prorenoate and spironolactone in normal man.
Ramsay L; Harrison I; Shelton J; Tidd M
Clin Pharmacol Ther; 1975 Oct; 18(4):391-400. PubMed ID: 1100306
[TBL] [Abstract][Full Text] [Related]
13. Effect of fludrocortisone and spironolactone on sodium and potassium losses in secretory diarrhea.
Wenzl HH; Fine KD; Santa Ana CA; Porter JL; Fordtran JS
Dig Dis Sci; 1997 Jan; 42(1):119-28. PubMed ID: 9009126
[TBL] [Abstract][Full Text] [Related]
14. ENaC expression correlates with the acute furosemide-induced K
Ayasse N; Berg P; Leipziger J; Sørensen MV
Physiol Rep; 2021 Jan; 9(1):e14668. PubMed ID: 33410279
[TBL] [Abstract][Full Text] [Related]
15. Effect of spironolactone on electrolytes, renin, ACTH and corticosteroids in the rat.
Chabert PR; Guelpa-Decorzant C; Riondel AM; Vallotton MB
J Steroid Biochem; 1984 Jun; 20(6A):1253-9. PubMed ID: 6087026
[TBL] [Abstract][Full Text] [Related]
16. Comparison of prorenoate potassium and spironolactone after repeated doses and steady state plasma levels of active metabolites.
McInnes GT; Shelton JR; Harrison IR; Perkins RM; Palmer RF
Br J Clin Pharmacol; 1982 Feb; 13(2):187-94. PubMed ID: 7059416
[TBL] [Abstract][Full Text] [Related]
17. The selective mineralocorticoid receptor modulator AZD9977 reveals differences in mineralocorticoid effects of aldosterone and fludrocortisone.
Bamberg K; William-Olsson L; Johansson U; Jansson-Löfmark R; Hartleib-Geschwindner J
J Renin Angiotensin Aldosterone Syst; 2019; 20(1):1470320319827449. PubMed ID: 30813831
[TBL] [Abstract][Full Text] [Related]
18. Spironolactone dose-response relationships in healthy subjects.
McInnes GT; Perkins RM; Shelton JR; Harrison IR
Br J Clin Pharmacol; 1982 Apr; 13(4):513-8. PubMed ID: 7066166
[TBL] [Abstract][Full Text] [Related]
19. Evidence that high dose cortisol-induced Na+ retention in man is not mediated by the mineralocorticoid receptor.
Montrella-Waybill M; Clore JN; Schoolwerth AC; Watlington CO
J Clin Endocrinol Metab; 1991 May; 72(5):1060-6. PubMed ID: 1850752
[TBL] [Abstract][Full Text] [Related]
20. Early and late adjustment to potassium loading in humans.
Rabelink TJ; Koomans HA; Hené RJ; Dorhout Mees EJ
Kidney Int; 1990 Nov; 38(5):942-7. PubMed ID: 2266680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
